Targeted Cancer Therapies in Context: FDA’s Pazdur on Companion Diagnostics
This article was originally published in RPM Report
Executive Summary
If you are interested in developing a novel targeted therapy for cancer—and these days, who isn’t?—FDA’s top cancer drug reviewer has a few ideas to keep in mind. Here’s one hint: almost everything is much simpler when the drug is very effective.